ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1931

Anti-Ku Antibodies: A Case Series

Raquel Ugena García1, Cristina Calomarde Gomez1, Joan Climent2 and Lourdes Mateo Soria2, 1Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Badalona, Spain

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), autoimmune diseases, immunology, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs), particularly overlap syndromes. However, controversies exist regarding their clinical significance and their relationship with SADs or some of their manifestations. Objective: To describe the clinical and immunological characteristics of a case series of patients with positive anti-Ku antibodies.

Methods: Descriptive study of a cohort of patients from a university hospital with positive anti-Ku antibodies between 2017 and 2022. Clinical variables (Raynaud’s phenomenon, arthritis, arthralgia, myalgia, muscle weakness, dyspnea, dysphagia, diffuse interstitial lung disease (DILD)), complementary investigations (pulmonary function tests (PFTs), high-resolution computed tomography (HRCT), capillaroscopy), and autoimmune study (ANA ENA, anti-DNA, complement study, anti-PM scl 75 antibodies, anti-PM scl 100 antibodies, CENP-B, antiphospholipid antibodies, rheumatoid factor (RF), and anti-citrullinated peptide antibodies (ACPA)) were analyzed. Finally, clinical diagnostic orientation, diagnosis based on systemic autoimmune disease (SAD) criteria, or final diagnosis of non-SAD pathologies were recorded.

Results: A total of 17 patients positive for anti-Ku antibodies were identified, of whom 14 were women (82.4%) with a mean age of 57 years and a median follow-up of 43 months. The clinical manifestations presented were as follows: arthralgia (13; 76.5%), arthritis (8; 47.1%), myalgia (6; 35.3%), myositis (2; 11.8%), muscle weakness (2; 11.8%), dysphagia (1; 5.9%), dyspnea (4; 23.5%), and Raynaud’s phenomenon (3; 17.6%). All patients had positive ANA, of which 8 cases (47.1%) exhibited a nucleolar pattern, 8 cases (47.1%) showed a fine speckled pattern, and only 1 case had a centromeric dot-like pattern. A total of 8 patients underwent high-resolution computed tomography (HRCT), of which 2 cases (25%) presented a ground-glass opacities pattern, 2 cases (25%) had pulmonary thromboembolism, and 2 cases (25%) had one or multiple neoplastic pulmonary nodules. Pulmonary function tests (PFTs) were performed in 7 cases, with 3 cases (42.9%) showing normal results, 2 cases (28.6%) displaying an obstructive pattern, and 2 cases (28.6%) demonstrating a restrictive pattern. Capillaroscopy was performed on 4 patients (3 normal results, 1 non-specific pattern). A diagnosis of neoplasia was established in 5 cases (29.4%). Only 6 patients (35.3%) met the criteria for systemic autoimmune disease (SAD), including 3 cases of systemic lupus erythematosus (one of them with associated antiphospholipid syndrome), 2 cases of Sjögren’s syndrome, and 1 case of systemic sclerosis.

Conclusion: In our case series, the clinical and laboratory characteristics were highly heterogeneous. The presence of anti-Ku antibodies was associated with the diagnosis of a systemic autoimmune disease (SAD) in just over one-third of the cases.


Disclosures: R. Ugena García: None; C. Calomarde Gomez: None; J. Climent: None; L. Mateo Soria: None.

To cite this abstract in AMA style:

Ugena García R, Calomarde Gomez C, Climent J, Mateo Soria L. Anti-Ku Antibodies: A Case Series [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/anti-ku-antibodies-a-case-series/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ku-antibodies-a-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology